11^th World Congress on Neuropharmacology May 06-07, 2019 Prague, Czech Republic

Market Analysis of Global Pharmaceutical Industries:

Prague is the largest city in the Czech Republic with a population of 1,3 mln inhabitants in 2016, amounting to 12% of the population of the Czech Republic. It is the capital city of the Czech Republic (CR) and politically, economically and culturally the most important city in the country.

Czech Republic’s Exports: Medicinal and Pharmaceutical Product was reported at 653,117.21 USD th in Dec 2016. This records an increase from the previous number of 632,784.52 USD th for Dec 2015. Czech Republic’s Exports: Medicinal and Pharmaceutical Product data is updated yearly, averaging 244,129.63 USD th from Dec 1995 to 2016, with 22 observations. The data reached an all-time high of 724,933.22 USD th in 2014 and a record low of 75,806.94 USD th in 1995. Czech Republic’s Exports: Medicinal and Pharmaceutical Product data remains active status in CEIC and is reported by United Nations Conference on Trade and Development. 

For more info: https://neuro.pharmaceuticalconferences.com/europe/

The global $1.12 trillion market in 2022, will rise at a faster clip during 2016-2020, then slow down a bit as major patent expiration take hold. It is expected that the global market declined by 1.0% in 2015, but will grow by 4.8% this year. Prescription sales excluding generics will rise 4.4% this year, and expected to reach $1.006 trillion in 2022. Generics sales will increase from $73 billion in 2015 to $115 billion in 2022, and constitute 10.2% of prescription sales at that point only 0.3 percentage points more than it is now.

The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%.

The global revenue for single use technology reached $1.4 billion and $1.7 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.7% to nearly $3.0 billion for the period 2014-2019.

Current Market Trends:

By international standards, Czech healthcare services are excellent in terms of quality and availability of treatment. Devices used to monitor symptoms and manage disease are in growing demand. The most common cause of death is circulatory system diseases (heart disease, stroke, etc.). Czechs continue to be heavy smokers and the air in many industrial cities is somewhat polluted. Growing interest in joint Czech-U.S. projects in the health care field could generate new opportunities for U.S. medical equipment providers. eHealth and telemedicine have been much-discussed topics in the Czech Republic.

The Czech Republic is a popular destination for medical tourism. It is known for reasonably priced quality treatment. Aesthetic medicine procedures, IVD treatment, obesity treatment and gynecological procedures are in the highest demand.

Socio-economic profile:

High level of urbanization, concentration of many functions and the proximity of key players in the capital makes Prague a distinct center of development at a national level and places Prague above the other regions in nearly all of the structural indicators. For instance, it accounts for approximately one-quarter of the Czech GDP (24,4%, Eurostat 2017). 

As for the economy, Prague has a unique position within the Czech Republic: it is the economic center of the state and also a center for intermediation when it comes to multinational economic relations in the whole state.

The total GDP in Prague amounts to 40,7 billion (PPS) and the GDP per capita is at 51.400 (PPS per inhabitant, Eurostat 2017).With this GDP per capita the region reached 203% of the Czech Republic’s average. At present, Prague exceeds the average values for the entire EU-28 (GDP per capita in Prague at 178% of the EU average). Higher GDP (generally typical for a metropolis) is related to a higher level of wages, localization of activities with a high added value and the concentration of central bodies of both the public and private sector..

Recent data from the European Federation of Pharmaceutical Industries and Associations determines the overall market size as roughly USD 2.4 billion. Though comparatively smaller when juxtaposed against some of the country's larger neighbors, the growth trajectory nonetheless appears rosy with pharma sales widely predicted to increase by as much as USD 1.27 billion by 2020.

Why Prague?

Prague is the Historical, political and Tourism capital of Czech Republic Prague was historical capital of Bohemia situated near to North West of Vltava river, who gave the city name by its. The amount of tenants in the city of Prague  is 2.2 million people. It is a most Eco Heritage city on the planet and home to true blue note worthy focuses. Prague climate is very cold climate at winters and little summer season, the city played major roles in the Bohemian and Protestant Reformation. The city is both a helpful and division and structures within and focal station of the Prague Castle and Bohemia River Region. Prague the accepted "city of a hundred spires & the golden city is more finished the place saw by the entire world for its progress, thoughtful intrigue, and Beauty. The city covers a zone of 1,106.36  which solidifies two regions, the Prague and the Czechia.

Why to attend???

Neuropharmacology Conferences provides a worldwide stage to trading thoughts and make us feel great about the most recent advancements in drug discovery and health care services. Chance to listen the introductions conveyed by Eminent Scientists from everywhere throughout the world.

Members Associated with Neuropharmacology Research:

Leading health care professionals , Doctors, Professors, Associate Professors, Research fellows, Directors, Deans and many more from leading universities, companies and medical research institutions, hospitals sharing their novel researches in the arena of Healthcare & Medicine.

Academia   30%

Industry      20%

Hospitals    30%

Others         20%

Summary:

The health care sector is very active and prominent in the Czech Republic. In 2015, healthcare expenditures reached $13.1 billion. Most of the expenditures were covered by mandatory healthcare insurance and other public sources. Private expenditures accounted for only $2.2 billion. The Czech Republic spends 7.5 percent of its GDP on healthcare.

Although the government is examining ways to reduce healthcare expenses, including limiting purchases of expensive equipment and pharmaceuticals or adopting e-tenders, the Czech Republic offers strong opportunities for medical device companies. Expected growth in the sector over the next couple years is around six percent.     

Current Demand:

The best market opportunities are for cutting-edge, high-quality sophisticated medical equipment, especially equipment that increases efficiency and reduces lengths of hospital stays.

Reimbursement:

The Czech Republic is a highly developed, open market with liberal policies and intense competition. One of the challenges manufacturers and importers of medical devices and pharmaceuticals will face is getting the product on the reimbursement scheme that is covered by the insurance companies. This can, in some cases, be a time-consuming process. There are seven health insurance companies in the Czech Republic, General Insurance Company (Vseobecna ydravotni pojistovna, VZP) is the largest insurer.

Universities Associated with Neuropharmacology in Prague:

• Charles University
• Masaryk University
• Palacky university Olomouc
• Czech Universities of Lifesciences
• Brno University of Technology
• Palacký University Olomouc
• University of Chemistry and Technology Prague
• Czech University of Life Sciences Prague
• Ostrava University
• Technical University of Ostrava
• Tomas Bata University in Zlín
• University of Pardubice
• University of West Bohemia
• Technical University of Liberec
• University of South Bohemia (USB) in Ceske Budejovice

Top Universities around the Globe:

• Anglia Ruskin University
• Arcada University of Applied Sciences
• Centre for Caring Sciences: Uppsala, Sweden
• CEU Cardinal Herrera University
• Dublin City University
• Karlova University
• Keele University
• King's College London
• Sevilla University
• University of Kuopio
• University of London
• University of Maribor
• University of Tampere

Target Audience:

• Professors
• Doctors
• Physicians
• Researchers
• Pharmacists
• Training Institutes
• Business Entrepreneurs
• Supply Chain companies
• Head of Department
• Health Economists
• Genetic Professionals
• Bio instruments Professionals
• Bio-informatics Professionals
• Pharmaceutical Industrial Giants

Major Neuropharmacology related Associations:

• Society For Neuroscience
• International Neuroethics Society
• American Neurological Association
• American Psychological Association
• Southern Clinical Neurological Society
• The American Society of Neuroimaging
• International Neuropsychological Society
• Society for Behavioral Neuroendocrinology
• American Clinical Neurophysiology Society
• American Board Of Psychiatry And Neurology, Inc.
• National Institute Of Environmental Health Sciences
• International Parkinson and Movement Disorder Society
• International Parkinson And Movement Disorder Society

Leading Hospitals in Prague:

• Canadian Medical
• Prague Psychiatric Center
• General Teaching Hospital
• Bulovka University Hospital
• Children's Hospital, Cernopolni
• Central Military Hospital Prague

Leading Hospitals in Czech Republic:

• Slaný Hospital
• Tábor Hospital
• Bílina Hospital
• Motol University Hospital
• Psychiatric Hospital Bohnice
• Plastic Surgery Hospital - Berkova Street

Top Hospitals Associated with Neuropharmacology Research in World:

• Mayo Clinic
• EI Camino Hospital
• EI Camino Hospital
• John Hopkins Medicine
• Tampa General Hospital
• UNM Neurology Centre
• Massachusetts General Hospital
• Jefferson Hospital for Neuroscience Huntington Hospital

Companies Associated with neuropharmacology Research in World are:

• Novartis
• Otsuka
• Biogen Idec
• Pfizer
• Eisai
• Bayer
• Teva
• Lilly
• Lundbeck
• Merck KGaA
• AstraZeneca
• GlaxoSmithKline
• Johnson & Johnson
• Bristol-Myers Squibb